Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors

Molecular Cancer

Volumn 8, Issue , 2009, Pages

  Landais, Igor ^a   Hiddingh, Sanne ^a   McCarroll, Matthew ^a   Yang, Chao ^b   Sun, Aiming ^b   Turker, Mitchell S ^c   Snyder, James P ^b   Hoatlin, Maureen E ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; FANCONI ANEMIA GROUP D2 PROTEIN; HYDROXYUREA; MITOMYCIN C; ATM PROTEIN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; DRUG DERIVATIVE; FANCD2 PROTEIN, HUMAN; KETONE; MITOMYCIN; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL SURVIVAL; CONTROLLED STUDY; DENSITOMETRY; DNA CROSS LINKING; DRUG ACTIVITY; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME INHIBITION; FANCONI ANEMIA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; UBIQUITINATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; HELA CELL; METABOLISM; XENOPUS;

ANIMALS; CELL CYCLE PROTEINS; CURCUMIN; DNA-BINDING PROTEINS; DRUG SYNERGISM; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; HELA CELLS; HUMANS; KETONES; MITOMYCIN; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; XENOPUS;

EID: 74549187963     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-133     Document Type: Article

References (51)

1. Kalb R, Neveling K, Nanda I, Schindler D, Hoehn H. Fanconi anemia: causes and consequences of genetic instability. Genome Dyn 2006, 1:218-242. full_text, 18724063.
2. de Winter JP, Joenje H. The genetic and molecular basis of Fanconi anemia. Mutat Res 2008,
3. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007, 8:735-748. 10.1038/nrg2159, 17768402.
4. Rahman N, Scott RH. Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum Mol Genet 2007, 16(Spec No 1):R60-66. 10.1093/hmg/ddm026, 17613548.
5. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV, D'Andrea AD. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006, 5:952-961. 10.1158/1535-7163.MCT-05-0493, 16648566.
6. Landais I, Sobeck A, Stone S, LaChapelle A, Hoatlin ME. A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway. Int J Cancer 2009, 124:783-792. 10.1002/ijc.24039, 19048618.
7. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008, 26:3785-3790. 10.1200/JCO.2008.16.0812, 18591545.
8. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134. 10.1056/NEJMoa0900212, 19553641.
9. Tuma RS. PARP inhibitors: will the new class of drugs match the hype?. J Natl Cancer Inst 2009, 101:1230-1232. 10.1093/jnci/djp315, 19738163.
10. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137:821-834. 10.1016/j.cell.2009.03.017, 19490892.
11. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848. 10.1016/j.cell.2009.05.006, 2768667, 19490893.
12. Kennedy RD, Chen CC, Stuckert P, Archila EM, De la Vega MA, Moreau LA, Shimamura A, D'Andrea AD. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007, 117:1440-1449. 10.1172/JCI31245, 1847538, 17431503.
13. Czornak K, Chughtai S, Chrzanowska KH. Mystery of DNA repair: the role of the MRN complex and ATM kinase in DNA damage repair. J Appl Genet 2008, 49:383-396.
14. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008, 9:759-769. 10.1038/nrm2514, 18813293.
15. Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D, Majid A, Dyer M, Siebert R, Taylor AM, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007, 25:5448-5457. 10.1200/JCO.2007.11.2649, 17968022.
16. Fang NY, Greiner TC, Weisenburger DD, Chan WC, Vose JM, Smith LM, Armitage JO, Mayer RA, Pike BL, Collins FS, Hacia JG. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci USA 2003, 100:5372-5377. 10.1073/pnas.0831102100, 154352, 12697903.
17. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007, 595:1-75. full_text, 17569205.
18. Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, Hollingshead MG, Kaur G, Sausville EA, Rickles FR, et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 2004, 12:3871-3883. 10.1016/j.bmc.2004.05.006, 15210154.
19. Adams BK, Cai J, Armstrong J, Herold M, Lu YJ, Sun A, Snyder JP, Liotta DC, Jones DP, Shoji M. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 2005, 16:263-275. 10.1097/00001813-200503000-00005, 15711178.
20. Sun A, Shoji M, Lu YJ, Liotta DC, Snyder JP. Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system. J Med Chem 2006, 49:3153-3158. 10.1021/jm051141k, 16722634.
21. Shoji M, Sun A, Kisiel W, Lu YJ, Shim H, McCarey BE, Nichols C, Parker ET, Pohl J, Mosley CA, et al. Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa. J Drug Target 2008, 16:185-197. 10.1080/10611860801890093, 18365880.
22. Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, Snyder JP, Hamel E, Giannakakou P. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 2008, 7:2409-2417. 2573855, 18682687.
23. Sobeck A, Stone S, Costanzo V, de Graaf B, Reuter T, de Winter J, Wallisch M, Akkari Y, Olson S, Wang W, et al. Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks. Mol Cell Biol 2006, 26:425-437. 10.1128/MCB.26.2.425-437.2006, 1346898, 16382135.
24. Sobeck A, Stone S, Hoatlin ME. DNA structure-induced recruitment and activation of the Fanconi anemia pathway protein FANCD2. Mol Cell Biol 2007, 27:4283-4292. 10.1128/MCB.02196-06, 1900049, 17420278.
25. Ben-Yehoyada M, Wang LC, Kozekov ID, Rizzo CJ, Gottesman ME, Gautier J. Checkpoint signaling from a single DNA interstrand crosslink. Mol Cell 2009, 35:704-715. 10.1016/j.molcel.2009.08.014, 19748363.
26. Wang LC, Stone S, Hoatlin ME, Gautier J. Fanconi anemia proteins stabilize replication forks. DNA Repair (Amst) 2008, 7:1973-1981. 10.1016/j.dnarep.2008.08.005, 2596863, 18786657.
27. Costanzo V, Robertson K, Bibikova M, Kim E, Grieco D, Gottesman M, Carroll D, Gautier J. Mre11 protein complex prevents double-strand break accumulation during chromosomal DNA replication. Mol Cell 2001, 8:137-147. 10.1016/S1097-2765(01)00294-5, 11511367.
28. Di Virgilio M, Ying CY, Gautier J. PIKK-dependent phosphorylation of Mre11 induces MRN complex inactivation by disassembly from chromatin. DNA Repair (Amst) 2009,
29. Lupardus PJ, Byun T, Yee MC, Hekmat-Nejad M, Cimprich KA. A requirement for replication in activation of the ATR-dependent DNA damage checkpoint. Genes Dev 2002, 16:2327-2332. 10.1101/gad.1013502, 187437, 12231621.
30. Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res 2007, 67:7395-7405. 10.1158/0008-5472.CAN-07-1015, 17671210.
31. Jana NR, Dikshit P, Goswami A, Nukina N. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem 2004, 279:11680-11685. 10.1074/jbc.M310369200, 14701837.
32. Kasinski AL, Du Y, Thomas SL, Zhao J, Sun SY, Khuri FR, Wang CY, Shoji M, Sun A, Snyder JP, et al. Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol 2008, 74:654-661. 10.1124/mol.108.046201, 2638506, 18577686.
33. Otsuki T, Young DB, Sasaki DT, Pando MP, Li J, Manning A, Hoekstra M, Hoatlin ME, Mercurio F, Liu JM. Fanconi anemia protein complex is a novel target of the IKK signalsome. J Cell Biochem 2002, 86:613-623. 10.1002/jcb.10270, 12210728.
34. Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, Yang X, Iotzova VS, Clarke W, Strnad J, et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 2003, 278:1450-1456. 10.1074/jbc.M209677200, 12403772.
35. Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D'Andrea AD. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 2002, 100:2414-2420. 10.1182/blood-2002-01-0278, 12239151.
36. Duckworth-Rysiecki G, Cornish K, Clarke CA, Buchwald M. Identification of two complementation groups in Fanconi anemia. Somat Cell Mol Genet 1985, 11:35-41. 10.1007/BF01534732, 3919452.
37. Rai R, Peng G, Li K, Lin SY. DNA damage response: the players, the network and the role in tumor suppression. Cancer Genomics Proteomics 2007, 4:99-106.
38. Wang ZQ, Stingl L, Morrison C, Jantsch M, Los M, Schulze-Osthoff K, Wagner EF. PARP is important for genomic stability but dispensable in apoptosis. Genes Dev 1997, 11:2347-2358. 10.1101/gad.11.18.2347, 316515, 9308963.
39. Ak T, Gulcin I. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact 2008, 174:27-37. 10.1016/j.cbi.2008.05.003, 18547552.
40. Patro BS, Rele S, Chintalwar GJ, Chattopadhyay S, Adhikari S, Mukherjee T. Protective activities of some phenolic 1,3-diketones against lipid peroxidation: possible involvement of the 1,3-diketone moiety. Chembiochem 2002, 3:364-370. 10.1002/1439-7633(20020402)3:4<364::AID-CBIC364>3.0.CO;2-S, 11933238.
41. Dupre A, Boyer-Chatenet L, Sattler RM, Modi AP, Lee JH, Nicolette ML, Kopelovich L, Jasin M, Baer R, Paull TT, Gautier J. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol 2008, 4:119-125. 10.1038/nchembio.63, 18176557.
42. Gurtan AM, Stuckert P, D'Andrea AD. The WD40 repeats of FANCL are required for Fanconi anemia core complex assembly. J Biol Chem 2006, 281:10896-10905. 10.1074/jbc.M511411200, 16474167.
43. Aleo E, Henderson CJ, Fontanini A, Solazzo B, Brancolini C. Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. Cancer Res 2006, 66:9235-9244. 10.1158/0008-5472.CAN-06-0702, 16982768.
44. Sobeck A, Stone S, Landais I, de Graaf B, Hoatlin ME. The Fanconi anemia protein FANCM is controlled by FANCD2 and the ATR/ATM pathways. J Biol Chem 2009, 284:25560-25568. 10.1074/jbc.M109.007690, 19633289.
45. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000, 14:1448-1459. 10.1101/gad.840500, 316686, 10859164.
46. Ho GP, Margossian S, Taniguchi T, D'Andrea AD. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol 2006, 26:7005-7015. 10.1128/MCB.02018-05, 1592857, 16943440.
47. Ishiai M, Kitao H, Smogorzewska A, Tomida J, Kinomura A, Uchida E, Saberi A, Kinoshita E, Kinoshita-Kikuta E, Koike T, et al. FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nat Struct Mol Biol 2008, 15:1138-1146. 10.1038/nsmb.1504, 18931676.
48. Shu HG, Brown A, Yoon Y, Gao H, Purcell J, Snyder JP, Liotta DC, Shim H. Radiosensitization of glioma cells with the curcumin analogs EF24 and UBS109. AACR 99th Annual Meeting 2008,
49. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007, 25:197-206. 10.1038/nbt1284, 17287757.
50. Yang K, Bai H, Ouyang Q, Lai L, Tang C. Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol 2008, 4:228. 10.1038/msb.2008.60, 2673713, 18985027.
51. Gage BM, Alroy D, Shin CY, Ponomareva ON, Dhar S, Sharma GG, Pandita TK, Thayer MJ, Turker MS. Spontaneously immortalized cell lines obtained from adult Atm null mice retain sensitivity to ionizing radiation and exhibit a mutational pattern suggestive of oxidative stress. Oncogene 2001, 20:4291-4297. 10.1038/sj.onc.1204509, 11466609.